Mastodon

Octanyne (Lyophilisate) Instructions for Use

ATC Code

B02BD04 (Blood coagulation factor IX)

Active Substance

Human coagulation factor IX

Human coagulation factor IX (Ph.Eur. European Pharmacopoeia)

Clinical-Pharmacological Group

Blood coagulation factor IX preparation

Pharmacotherapeutic Group

Hemostatic agent

Pharmacological Action

Hemostatic agent used in hemophilia B. During blood coagulation, coagulation factor IX is activated by factor XIa. The active form of coagulation factor IX – factor IXa – in combination with coagulation factor VIII activates factor X, which, in turn, promotes the conversion of prothrombin to thrombin and the formation of a fibrin clot.

Pharmacokinetics

In patients with hemophilia B, T1/2 is 1 day.

Indications

Prophylaxis and treatment of bleeding in hemophilia B, acquired coagulation factor IX deficiency.

ICD codes

ICD-10 code Indication
D67 Hereditary factor IX deficiency
D68.4 Acquired coagulation factor deficiency
R58 Hemorrhage, not elsewhere classified
ICD-11 code Indication
3B11.Z Hereditary factor IX deficiency, unspecified
MG27 Hemorrhage, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Determine the dosage individually based on the severity of hemorrhage, body weight, and the patient’s clinical condition.

Calculate the required dose in International Units (IU).

Administer intravenously by slow infusion.

For minor spontaneous bleeding or for routine prophylaxis, administer a dose of 20-40 IU/kg.

For moderate bleeding or minor surgical procedures, administer a dose to achieve a target factor IX level of 30-60% of normal.

For major bleeding, life-threatening hemorrhage, or major surgery, administer a dose of 60-100 IU/kg to achieve a target factor IX level of 80-100% of normal.

Adjust the dose and frequency based on regular monitoring of plasma factor IX activity.

Monitor the pulse rate before and during infusion.

Reduce the infusion rate or discontinue administration if a significant increase in pulse rate occurs.

Adverse Reactions

Allergic reactions: chills, fever, urticaria are possible.

From the digestive system: nausea, vomiting are possible.

From the blood coagulation system: cases of intravascular coagulation and development of thrombosis during surgical interventions and in patients with liver diseases have been reported.

Other: headache, feeling of heat are possible.

Contraindications

Hypersensitivity to coagulation factor IX.

Use in Pregnancy and Lactation

Currently, there is insufficient experience with the use of coagulation factor IX during pregnancy and lactation (breastfeeding).

Use in Hepatic Impairment

Use with caution in patients with liver diseases.

Pediatric Use

Use with caution in newborn infants.

Special Precautions

Use with caution in patients with liver diseases, in the postoperative period, in newborns, and in other cases of increased risk of thrombosis and DIC. If DIC syndrome is suspected or present, administration can be carried out only after this process has been stopped, preferably in combination with antithrombin III.

The use of coagulation factor IX in patients with hemophilia B with a recent thrombosis or acute myocardial infarction in cases of bleeding development requires thorough justification.

During administration, it is necessary to monitor the degree of increase in coagulation factor IX values, which should average 25% and should not exceed 50%; pulse rate before and during the administration of coagulation factor IX. If the pulse rate increases significantly, it is necessary to slow down the infusion rate of the drug or stop its administration.

Patients with allergic diseases are recommended to receive prophylactic corticosteroids and antihistamines. In case of allergic or anaphylactic reactions, administration should be stopped immediately and appropriate therapy should be prescribed.

When using drugs made from human blood or plasma, the possibility of contracting infectious diseases cannot be completely excluded.

Drug Interactions

Coagulation factor IX eliminates excessive anticoagulant effect and bleeding caused by warfarin.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Octapharma Pharmazeutika Produktionsges m.b.H. (Austria)

Dosage Form

Bottle Rx Icon Octanyne Lyophilizate for the preparation of solution for infusion 250 IU: fl. 1 pc. with solvent and sterile equipment

Dosage Form, Packaging, and Composition

Lyophilizate for the preparation of solution for infusion 1 vial
Blood coagulation factor IX 250 IU

Solvent: water for injections – 5 ml.
Vials (1) in a set with solvent (vial), disposable syringe, double-ended needle, filter needle, intravenous administration set, 2 alcohol swabs – cardboard packs.

Marketing Authorization Holder

Octapharma Pharmazeutika Produktionsges m.b.H. (Austria)

Dosage Form

Bottle Rx Icon Octanyne Lyophilized powder for the preparation of an injection solution 500 IU: vial 1 pcs. in a set with a solvent and sterile equipment

Dosage Form, Packaging, and Composition

Lyophilized powder for injection 1 vial
Blood coagulation factor IX 500 IU

Solvent: water for injections – 5 ml.

Vials (1) in a set with solvent (vial), disposable syringe, double-ended needle, filter needle, intravenous administration set, 2 alcohol swabs – cardboard packs.

TABLE OF CONTENTS